- Home
- PNI vs BOLD Comparison
PNI vs BOLD Comparison
Compare PNI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PNI | BOLD |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 36.5M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | PNI | BOLD |
|---|---|---|
| Price | $6.89 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 38.9K | ★ 151.2K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.43 | $0.96 |
| 52 Week High | $7.20 | $1.72 |
Technical Indicators
Market Signals| Indicator | PNI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.41 | 54.54 |
| Support Level | $6.88 | $1.12 |
| Resistance Level | $6.98 | $1.55 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.59 | 46.00 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.